EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae

Megan Crumpler, Susan E Realegeno, Salika M Shakir iD, Shelby M Hutton, William Davis iD, Julio C Ayala iD, Amanda C Smith iD, Barbara Van Der Pol iD

Clinical Infectious Diseases · 24.02.2026 · 82 (Supplement_1) · S19-S35

DOI: 10.1093/cid/ciaf696 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, online erschienen am 24.02.2026. Verfasst von Megan Crumpler und 7 weiteren Autor:innen. Beteiligte Einrichtung: Orange County Health Care Agency, Irvine, California, USA. Hauptthemen laut MEDLINE: Chlamydia trachomatis, Neisseria gonorrhoeae, Gonorrhea, Chlamydia Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CDC HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are the most commonly reported sexually transmitted infections (STIs) in the United States, and their accurate diagnosis is critical for preventing serious health outcomes. Nucleic acid amplification tests (NAATs) are still considered the gold standard for the laboratory diagnosis of chlamydia and gonorrhea due to their high sensitivity and specificity. Since the 2014 CDC laboratory recommendations, several key improvements to FDA-cleared NAATs have been made including expanded specimen types, technology, and process improvements.

Methods

We conducted a systematic literature search and a narrative review focused on the performance of laboratory-based molecular diagnostics for CT and NG. This systematic review evaluated 145 studies to assess current diagnostic performance, focusing on six key areas: FDA-cleared diagnostic NAATs, self-collected specimens, pooling strategies, time to negativity, confirmatory/repeat testing, and LGV diagnostics.

Results

Many assays now include claims for clinician-collected extragenital specimens and self-collected vaginal swabs with high sensitivity (>90%) and specificity (>98%), and the recent FDA authorization of the first self-collection kit for nonclinical settings represents a major milestone in STI care access. However, no NAATs currently have claims for patient-collected extragenital specimens, despite strong evidence of comparable performance and high patient acceptability. Newer versions of assays incorporate dual targets for both CT and NG to enhance positive predictive value and reduce diagnostic escape. While no FDA-cleared assays exist for LGV differentiation, several laboratory-developed tests show promise.

Conclusions

Future directions include expanding FDA clearance for self-collected extragenital specimens and developing viability assays to better distinguish active infection from residual nucleic acids. Together, these advances underscore the progress in CT/NG testing and highlight opportunities to further improve diagnostic reach and clinical relevance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chlamydia trachomatisNeisseria gonorrhoeaeGonorrheaChlamydia InfectionsMolecular Diagnostic TechniquesHumansSensitivity and SpecificityNucleic Acid Amplification TechniquesUnited StatesFemaleSpecimen Handling

Stichwörter der Autor:innen

NAATSTIchlamydiadiagnosticsgonorrhea

Autor:innen und Institutionen

  • Orange County Health Care Agency, Irvine, California, USA.
  • Quest Diagnostics, San Juan Capistrano, California, USA.
  • University of Utah/ARUP Laboratories, Salt Lake City, Utah, USA.
  • Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.

ORCID-Profile: Salika M Shakir, William Davis, Julio C Ayala, Amanda C Smith, Barbara Van Der Pol

Förderung

  • CDC HHS
  • Centers for Disease Control and Prevention

Zitieren

APA

Crumpler, M., Realegeno, S. E., Shakir, S. M., Hutton, S. M., Davis, W., Ayala, J. C., Smith, A. C., & Van Der Pol, B. (2026). Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae. Clinical Infectious Diseases, 82(Supplement_1), S19-S35. https://doi.org/10.1093/cid/ciaf696

Vancouver

Crumpler M, Realegeno SE, Shakir SM, Hutton SM, Davis W, Ayala JC, et al. Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae. Clinical Infectious Diseases. 2026;82(Supplement_1):S19-S35. doi:10.1093/cid/ciaf696

BibTeX
@article{Crumpler2026,
  author = {Crumpler, Megan and Realegeno, Susan E and Shakir, Salika M and Hutton, Shelby M and Davis, William and Ayala, Julio C and Smith, Amanda C and Van Der Pol, Barbara},
  title = {Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {Supplement_1},
  pages = {S19--S35},
  doi = {10.1093/cid/ciaf696}
}
Kostenlos starten →